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1. Introduction 
Relatively little is known about proteins in peritoneal effluent, that are lost or changed 
during peritoneal dialysis(PD) and in different  diseases, leaving various unclear questions. 
Biomarkers that can indicate damages caused by peritoneal dialysis, like cancer antigen 125 
and interleukin-6 are some exemples. Therefore, tools such as proteomic approaches that 
can globally identify, characterize, and quantify a set of proteins and their changes in 
peritoneal dialysate, could shed light to the mechanisms of peritonitis and membrane 
damage. The availability of fluid from dialysis for study and the potential importance of 
specific protein change during peritoneal dialysis making this a potentially fruitful area for 
further observation. Since the renal community is embracing proteomic technologies at an 
increasing rate, growing numbers of studies that would be carried out through this process 
can be envisaged. In this chapter we intend to introduce basic proteomic tools and highlight 
important advances in peritoneal dialysis using proteomic approaches as well as the future 
perspective that proteomic tools can contribute in the field of peritoneal dialysis  
2. Proteomic tools 
In recent years, proteomic analyses of particular biological samples or clinical samples have 
drawn much interest and provided much information. Proteomic tools such as two 
dimensional gel electrophoresis (2DE) and mass spectrometry analysis have been widely 
applied in the study of body fluids, e.g. cerebrospinal fluid, pleural and pericardial effusions 
(Liu et al. 2008; Tyan et al. 2005a; Tyan et al. 2005b), and urine (Bennett et al. 2008; Tan et al. 
2008). For peritoneal dialysis, several issues have been addressed as described in the 
following sections. . The advantages and disadvantages of the various techniques have been 
reviewed previously (Fliser et al. 2007; Mischak et al. 2007). 
2.1 Two dimensional gel electrophoresis (2DE) 
Proteins are separated by isoelectric point and size. The protein spot can be visualized by gel 
staining. It is widely available and the posttranslational modification of the protein can be 
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revealed by separation of charge forms. However, low-abundance, large, and hydrophobic 
proteins are difficult to be detected. 2DE is technically demanding and time-consuming. The 
low number of independent datasets and the high variability of the gel make the definition 
of biomarkers difficult or even impossible. 2DE with fluorescent labeling of proteins before 
separation in gel (DIGE) has been proposed to improve reproducibility. Additional expense 
for fluorescent dyes and three color imaging system is required. 
2.2 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
Proteins are digested before separation by liquid chromatography coupled to MS 
instruments. MS detection is more sensitive than 2DE. It is easily automated, allowing 
analyzing a serious of samples. Drawback in comparison to 2DE is that information on the 
molecular mass of the actual biomarker as well as on any posttranslational modifications 
(PTM) is generally lost. This requires additional tools. 
2.3 Surface-enhanced laser desorption ionization (SELDI) 
Proteins are bound to affinity surface on a MALDI chip. Samples can be enriched for specific 
low-abundance proteins. Bound proteins are detected in a mass spectrometer. The SELDI 
technology draws a lot of interest because of its ease of use and its high throughput for 
biomarker discovery. However, the low-resolution of the mass spectrometer, the large 
amount of variability between labs, and its lack of reproducibility, hamper its potential 
clinical application (McLerran et al. 2008). 
2.4 Capillary electrophoresis coupled to mass spectrometry (CE-MS) 
Proteins were separated by elution time in CE and by size in MS. High reproducibility, 
robustness, high resolution and sensitivity make it a potential technique for biomarker 
discovery. Its limitation is that proteins can’t be identified without additional steps and only 
proteins/peptides <20 kDa can be analyzed. 
3. Analyses of peritoneal dialysis by proteomics tools 
3.1 Preliminary proteomic studies on peritoneal dialysis effluent 
A descriptive study was performed on the dialysate of nine paediatric PD children patients 
to obtain a representative overview of the proteome of peritoneal fluid (Raaijmakers et al. 
2008). None of the patients suffered from peritonitis in the 3 months before the collection. 
Proteins were resolved on the SDS-PAGE and the protein spots identification was achieved 
by nanoLC-MS/MS. A total of 189 proteins were identified, with 88 proteins shared by all 
the patients. The function of these shared proteins were classified into 8 classes. As listed in 
Table 1, acute phase proteins, complement factors, hormones, coagulation factors, and 
apolipoproteins were found. 
These factors were related to the number of frequently occurring proteins in the dialysate 
(Pecoits-Filho et al. 2004; Reddingius et al. 1995; Saku et al. 1989; van der Kamp et al. 1999). 
The proteome of PD fluid also reveals some interesting proteins, Gelsolin, intelectin, and 
parapxonase, which could possible involve in protecting the mesothelial cell damage and 
against infection, against parasites, and anti-atherogenic capacitities, respectively. The 
proteome of PD may help understand the functional mechanism of the peritoneum. 
www.intechopen.com
 Proteomics in Peritoneal Dialysis 
 
89 
 
Table 1. Protein classification according to function of the proteins present in all the patients, 
relative abundances are given with mean emPAI values [Adapted from (Raaijmakers et al. 
2008)] 
3.2 Dialysis-related peritonitis 
Peritonitis caused by CAPD may lead to peritoneal abnormalities. To search for potential 
biomarkers for peritonitis, Lin et al. have compared the proteome of peritoneal dialysate 
from 16 patients with and without peritonitis (Lin et al. 2008). Proteins were separated on 
2DE, indicating several differential expressed spots (Figure 1). 
 
  
Fig. 1. Protein map, obtained by 2DE, of protein lysates prepared from CAPD dialysis 
effluent without (left) and with (right) peritonitis. Proteins are first separated according to 
their pI using iso-electric focusing and then separated according to their respective 
molecular weight using (10%) SDS-PAGE. [Adapted from (Lin et al. 2008)] 
Samples were also analyzed by SELDI-TOF MS, revealing that signal peak at m/z of 11117.4 
only appeared in the peritonitis sample. This signal was identified as ǃ2-microglobulin by 
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using MALDI-TOF/TOF MS. Protein ǃ2-microglobulin has been linked to CAPD peritonitis 
in previous studies. In CAPD dialysate from patients with bacterial peritonitis, ǃ2-
microglobulin showed higher levels than in those without peritonitis (Carozzi et al. 1990). 
Minami et al. the level of ǃ2-microglobulin in the peritoneal dialysate was correlated with 
peritoneal injural (Minami et al. 2007). Using the protein profile approach, this study 
confirmed ǃ2-microglobulin as a biomarker for CAPD peritonitis.  
3.3 Different types of peritoneal membranes 
The efficacy and clinical outcome of CAPD depend on peritoneal membrane function. 
Peritoneal membranes can be classified as high (H), high average (HA), low average (LA), 
and low (L) transporters by using peritoneal equilibration test (PET). Whether there is a 
difference in proteins removed by different types of peritoneal membranes has been 
discussed in a study conducted by Sritippayawan et al. (Sritippayawan et al. 2007). They 
performed a proteomic analysis of peritoneal dialysate in CAPD patients with H, HA, LA, 
and L transport rates. Five patients were included for each group, makes up to 20 patient 
samples. Proteins from each sample were resolved in each 2D-gel (total 20 gels). 
Representative gels are shown in Figure 2. After gel visualization by staining and spot 
quantitation by image analysis software, the mean values of individual parameters were 
compared among the four different groups. Five proteins were found to show differed 
levels among groups. They were identified as serum albumin in a complex with myristic 
acid and triiodobenzoic acid, ǂ1-antitrypsin, complement component C4A, immunoglobulin 
κ light chain, and apolipoprotein A-I by MALDI-Q-TOF MS and MS/MS analyses. ELISA 
was used to confirm the difference expression of C4A and immunoglobulin κ in a set of 
other 24 patients. Functional significance of differential levels of these proteins may 
associate with dialysis adequacy, residual renal function, risk of peritonitis, and nutritional 
status. The level of serum albumin in a complex with myristic acid and triiodobenzoic acid 
was higher in the L LA groups, implying that the modified or complexed form of albumin 
may be associated with peritoneal membrane transport. The level of C4A was higher in H 
and HA group. In peritoneal dialysate, C4A originates from  vascular leakage, resulting in 
the lower C4A level in L group. The immunoglobulin κ light chain VLJ region, whose level 
was higher in H and HA groups also tended to be higher in patients with peritonitis. The 
higher level of immunoglobulin κ light chain VLJ region might be related to poorer function 
of neutrophils. Patients in H and HA group also had higher apolipoprotein A-I in peritoneal 
dialysate compared to L and LA groups, which may explain that high solute transporters 
are prone to develop atherosclerosis. 
3.4 The role of glucose in peritoneal dialysis 
The abdominal cavity is covered by the mesothelial cell (MC) layer. Peritoneal dialysis fluid 
may remove solutes and fluid from the patients due to its hypertonicity. Long period and 
frequent peritoneal dialysis could lead to structural and functional alterations of the MC 
layer, leading to a final failure of peritoneal dialysis (Davies et al. 2001; Heimburger et al. 
1990; Ho-dac-Pannekeet et al. 1997; Imholz et al. 1993; Williams et al. 2002). Hperosmolarity 
in peritoneal dialysis effluents is  generated by  high concentrations of glucose which could 
be degraded into carbonyl compounds as various glucose degradation products (GDPs) 
after heat sterilization (Linden et al. 1998; Nilsson-Thorell et al. 1993; Pischetsrieder 2000; 
Witowski and Jorres 2000; Witowski et al. 2003). These GDPs are reported as being  
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Fig. 2. Representative 2-D gel images of the PDE proteins derived from different types of 
peritoneal membranes. Proteins were precipitated with 75% ethanol, and an equal amount 
of total protein (200 íg) obtained from each patient was resolved in each 2-D gel (n ) 5 gels 
for each group; total n ) 20). The resolved protein spots were visualized by CBB-R250 stain. 
Quantitative intensity analysis and ANOVA with Tukey’s posthoc multiple comparisons 
revealed five protein spots whose intensity levels significantly differed among groups (see 
Table 2). These protein spots (labeled with numbers) were subsequently identified by 
MALDI-Q-TOF MS and MS/MS analyses. [Adapted from (Sritippayawan et al. 2007)] 
mitogenic and cytotoxic. Thus, peritoneal dialysis effluent is considered as a significant 
stressor for the MC layer (Breborowicz et al. 1995; Wieslander et al. 1991). To address this 
issue, a cell line derived from the MC layers was used as a model to study the glucose-
related pathways induced by high concentration of glucose (Lechner et al. 2010). Using two-
dimensional fluorescence-difference gel electrophoresis (DIGE), altered proteins upon 
glucose stress in Met-5A cell were revealed. A total of 947 spots were present in 32 gels (16 
controls, 16 glucose stress). A representative gel is shown in Figure 3. Among them, 140 
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spots were of differential expression under full-peritoneal dialysis fluid stress consisting of 
high glucose concentration, pH 5.8, and the presence of GDPs, when compared to untreated 
cells, of which 100 proteins can be identified by MALDI-MS and MS/MS techniques. 
Further studies on these factors suggested that glucose exposure alone was not sufficient to 
explain the differential abundant of these proteins, supporting the hypothesis that stressors, 
pH, lactate, and GDPs, might have essential impact for activation of the glucose –related 
pathways. . By comparing peritoneal dialysis effluent with different glucose concentrations, 
four proteins were found to be under-expressed in the highest osmolar solution. All of them 
were considered to be involved in the inflammatory processes. 
 
 
Fig. 3. CBB stained 2-DE gel of a MeT-5A cell lysate. Proteins, differently abundant after full-
PDF exposure and assigned to significantly enriched glucose associated pathways, are 
indicated with a circle and labeled with their Swiss-Prot entry names. Protein isoforms are 
distinguished by numbers in brackets. [Adapted from (Lechner et al. 2010)] 
Another laboratory works on analyzing the protein composition of peritoneal fluid from 
patients receiving peritoneal dialysis with different concentration of glucose (Cuccurullo et 
al. 2010). Peritoneal dialysis effluent with different glucose concentrations were revealed by 
2DE. The representative gels for each group are shown in Figure 4.  
Combining the data from 2DE and shotgun proteomics analysis, 151 non-redundant 
identifications were reached. Through the cellular component analysis, proteins related to 
extracellular region were over-expressed. As for the molecular function and biological 
process, proteins associated with protein binding and inflammatory processes were over-
represented. Four proteins, Alpha-1-antitrypsin (1603), fibrinogen beta chain (4308– 5303), 
transthyretin (4303 and 2101), and apolipoprotein A-IV (4208) were found to be under-
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expressed in the highest osmolar solution. The result provides potential targets for future 
therapeutic implementation in preventing inflammatory processes induced by the exposure 
to dialysis solutions. 
 
 
Fig. 4. Representative 2D gel images of PDE protein profiles from one (out of five) adult 
patient treated with peritoneal dialysis solutions differing for glucose percentages (A = 
glucose percentage 1.5%, B = glucose percentage 2.5%, C = glucose percentage 4.25%). 
Circled spots correspond to proteins whose expression undergoes quantitative changes. 
Alpha-1-antitrypsin (1603), fibrinogen beta chain (4308– 5303), transthyretin (4303 and 2101), 
apolipoprotein A-IV (4208). [Adapted from (Cuccurullo et al. 2010)] 
3.5 Peritoneal dialysate from diabetic patients 
Fluid overload related cardiovascular disease is one important factor to mortality in patients 
receiving CAPD (Brown et al. 2003). Other proposed mechanism is the glucotoxicity cause 
by the high concentration of glucose contained in PD fluid (Sitter and Sauter 2005).   
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Fig. 6. Representative 2DE gels for the DM samples (A) and the non-DM (B) samples. DM 
samples and non-DM samples were pooled separately for 2DE analysis (pH 4-7). A total of 
120 µg was used. The analysis of each group was repeated six times and two representative 
gels are shown. An average of 200 protein spots were detected in both gels. Among these, 17 
spots were found with higher levels in the peritoneal dialysate (indicated in A by arrows) 
and 9 spots were found with higher levels in the control samples (indicated in B by arrows) 
[Adapted from (Wang et al. 2010)] 
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Fig. 7. Western blotting of the identified proteins in five individual DM samples and two 
individual control samples: the mean band density of five DM samples and two control 
samples were calculated and fold change between the two groups was calculated by 
dividing the mean band density of the DM samples by that of the control samples; the mean 
density of the control groupwas adjusted as 1, and the fold changewas put in the bracket 
beloweach set of bands [(A) proteins, vitamin D-binding protein, haptoglobin and α-2-
microglobulin show higher expression levels in the DM samples than in the control samples; 
(B) proteins, complement C4-A and IGK@ protein show higher expression levels in the two 
control samples than in the five DM samples].[Adapted from (Wang et al. 2010)] 
However, the details of the pathogenic mechanism remain unclear. Protein changes between 
peritoneal dialysate from specific disease and normal peritoneal fluids may shed light to 
better understanding of the mechanism involved in peritoneal damage resulting from 
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peritoneal dialysis. For clinical application, altered proteins in the peritoneum may function 
as biomarkers for monitoring which functions as a non-invasive way of detecting peritoneal 
damage. Wang et al. have compared the diabetic peritoneal dialysate versus normal 
peritoneal fluid (Wang et al. 2010). From the 2DE (as shown in Figure 6), 26 protein spots 
were considered altered between two sample groups. 
According to the western confirmation results (Figure 7), vitamin D-binding protein, 
haptoglobin and ǂ-2-microglobulin showed higher levels in the DM samples, while 
complement C4-A and IGK@ protein were of lower levels compared to the control samples. 
The work concluded that the loss of some specific proteins may be due to a change in the 
permeability of the peritoneal membrane to middle-sized proteins or leakage from 
peritoneal inflammation. It has been reported that PD leads to loss of DBP, and this causes 
loss of vitamin D. Vitamin D deficiency results in reduced insulin secretion in rats and 
humans, and its replacement improves B cell function and glucose tolerance (Boucher et al. 
1995; Kumar et al. 1994; Norman et al. 1980; Tanaka et al. 1984). Thus the level of Vitamin D 
binding protein should be monitored after long-term PD. It has been suggested that 
haptoglobin may play a role in defending against haemoglobin toxicity, mainly renal 
toxicity (Lim et al. 2000). The observation of ǂ-2-microglobulin in dialysate may be 
indicative of high levels of ǂ-2-microglobulin in serum and a potential for amyloidosis. 
Complement activation happens in the peritoneal cavity in patients on chronic PD 
(Reddingius et al. 1995; Young et al. 1993), suggesting that local production of complement 
may be a possible inflammatory injury effectors in the initiation of chronic peritoneal 
damage. Lower levels of complement C4-A in dialysis effluent may indicate the beginning 
of peritoneal scleroses. The limited studies of the role of IGK@ protein in the peritoneum 
posted this protein a novel target for further investigation of its defect in dialysate, which 
may provide a new insight for peritoneal change or damage during PD. 
4. Concluding remarks and outlook 
Recent publication of potential biomarkers is only based on limited datasets in the absence 
of any validation. Future implementation of proteomics to the peritoneal dialysis will 
depend largely on establishment of generally accepted validity of the identified biomarkers. 
Development of standardization procedures for clinical proteomic studies is also required, 
including the sample collection procedures. However, these primary works suggested that 
proteome analysis may be a helpful tool to evaluate therapeutic effects of drugs on a 
molecular level. These studies may serve as a basis for the future identification of toxins and 
biomarkers for monitoring and improving the PD. Although it is evident that significant 
efforts, including larger studies are required to reach these goals, those studies also provide 
a possible platform for future diagnostic and therapeutic applications in the field of 
peritoneal dialysis and allowed the identification of potential targets to be used in 
preventing inflammatory processes induced by the exposure to dialysis solutions. Some 
reviews on this field claimed that recent findings underscore proteomic tools in defining 
molecules removed by the treatment modalities. Most of the studies were conducted by 
using 2DE which is widely used but also lacking in sensitivity and reproducibility. Thus, we 
can envisage that in the future, using rapidly evolved proteomic tools such as LC-MS/MS 
and accurate quantitative proteomic approaches such as iTRAQ and label free analyses will 
bring more information and novel insight into this field. 
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